Francis Johnson

Biotech September 27, 2017

NIH sees a need for speed in Traverse Biosciences

By GREGORY ZELLER // The National Institutes of Health has welcomed a rising Stony Brook biotech into its competitive Commercialization Accelerator Program. Traverse Biosciences, which is attempting to commercialize novel drug candidates for the treatment of inflammatory diseases affecting animals and humans, has landed one of 80 annual slots in the CAP, a nine-month program hosted by the NIH and the Larta Institute, a California-based networking group promoting international innovation. The NIH CAP – which…

Pharma August 8, 2017

Heads scratched as Chem-Master gets the boot

By GREGORY ZELLER // A biotech manufacturer with a 23-year history of servicing Stony Brook University researchers and startups is being evicted from the university’s Chemistry Building – and nobody seems entirely sure why. Chem-Master International, a producer of unique chemical compounds for research and commercial development, has operated inside the Chemistry Building since it launched in 1994, thanks to a “revocable permit” – special SUNY dispensation allowing nontraditional programs and outside entities to occupy…

Biotech February 14, 2017

New patent, new partnership for soaring Traverse

By GREGORY ZELLER // When a new U.S. patent is your second-biggest announcement of the day, you’re probably in a good place. It’s all smiles (with healthy teeth, of course) lately at Stony Brook-based Traverse Biosciences, which on Tuesday announced a new patent and a material transfer agreement with what CEO Joseph Scaduto dubbed “a top-10 global animal-health company” – essentially, an agreement to privately test flagship formula TRB-N0224 against a host of animal illnesses. That’s…